Noradrenalin Abcur (Noradrenaline Tartrate)

Noradrenaline tartrate acts as a direct agonist at alpha‑adrenergic receptors on vascular smooth muscle, causing strong vasoconstriction and increased systemic vascular resistance. It also stimulates beta‑1 receptors, providing a modest boost to cardiac output, together improving blood pressure in shock states.

The dosage of Noradrenalin Abcur is individualized by the treating physician based on the patient’s hemodynamic status, target blood pressure, and response to therapy. Clinicians typically start with a low infusion rate and titrate upward while monitoring vital signs.

The safety of Noradrenalin Abcur in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Noradrenalin Abcur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Noradrenalin Abcur is a first‑line sympathomimetic vasopressor, offering potent alpha‑adrenergic vasoconstriction with modest beta‑1 activity. Compared with agents like dopamine or phenylephrine, it provides a more predictable increase in vascular tone while maintaining some cardiac output, making it preferred in many shock protocols.

Noradrenalin Abcur should be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

The product is supplied as a sterile injectable solution for intravenous infusion. It is administered through a calibrated infusion pump or syringe driver, allowing precise titration of the dose while continuous blood pressure monitoring is performed.

Serious risks include severe hypertension, myocardial ischemia, tissue necrosis from extravasation, arrhythmias, and, in rare cases, cardiac arrest. Prompt recognition of adverse events and immediate adjustment or discontinuation of the infusion are essential to mitigate these risks.

Patients with known hypersensitivity to noradrenaline or any excipients, those with pheochromocytoma, or individuals with uncontrolled peripheral vascular disease should not receive Noradrenalin Abcur unless the benefits clearly outweigh the risks and close monitoring is ensured.